TL;DR: FemTech News November 2026, Funding Gaps and a Startup Launch Plan
This FemTech news, November, 2026 briefing shows you where women's health demand outruns capital, so you can claim an underfunded market early.
- The market gap is large. Freshcode projects FemTech will grow from $41 billion in 2024 to $98.8 billion by 2029. Only 4% of healthcare R&D targets women's health, and FemTech gets just 3% of digital health spending (CapShift).
- Funding stays lopsided. Between 2019 and 2023, endometriosis received $44 million while erectile dysfunction received $1.24 billion, about 28 times more. Less competition means openings, but you should plan for grants and impact capital.
- Clinical proof attracts the money. AI digital therapeutics for PCOS and AI breast imaging for dense tissue show funding moving away from simple cycle trackers. Privacy is becoming a reason buyers choose one product over another.
- These segments are least crowded: menopause, pelvic health, women's longevity, endometriosis and osteoporosis. For a closer look at one of them, read these menopause care trends.
- Founder Violetta Bonenkamp (Mean CEO) suggests these launch steps:
- Pick one condition.
- Run 30 customer and 5 clinician interviews.
- Decide whether your product is a wellness app or a medical device.
- Build privacy in from the first prototype.
- Prototype with no-code tools.
- Pilot with a clinic.
- Stack non-dilutive funding first.
Choose one underserved condition, book 10 customer interviews this week, and learn how full-stack FemTech care models are changing who pays for women's health products.
Check out other fresh startup news and trends that you might like:
This month’s FemTech news opens with a gap that refuses to close: the women’s health technology market is projected to grow from $41 billion in 2024 to $98.8 billion by 2029, and still only 4% of healthcare R&D (research and development) addresses women’s health issues. I am Violetta Bonenkamp, known in startup circles as Mean CEO. I run companies in parallel across Europe, including CADChain in deeptech and IP protection and Fe/male Switch, a women-first startup game and online incubator. I read FemTech reports the way an investor reads a balance sheet, looking for the mismatch between demand and supply. In November 2026 that mismatch is still HUGE, and it is the best reason for an entrepreneur to pay attention.
This briefing pulls together the most useful numbers, company signals and research on FemTech from sources such as Jones Day, CapShift, Freshcode, DelveInsight, FemTech Analytics and the Leeds School of Business at the University of Colorado Boulder. I also add my own analysis as a founder who scaled a team from about 4 to 25 people, secured national and EU-level grants, and spent years building practical scaffolding for women founders. You will get a list of stories worth tracking, a step-by-step guide to launching a FemTech venture, the mistakes I see founders repeat, and a few uncomfortable opinions. Let’s break it down.
What is FemTech, and why should founders care in November 2026?
FemTech, short for “female technology,” is the umbrella term for software, diagnostics, medical devices, wearables, telemedicine services and pharmaceuticals designed around women’s physiology and health needs. Danish entrepreneur Ida Tin, founder of the period and ovulation tracking app Clue, coined the term in 2016. The category covers reproductive health, menstrual health, pregnancy and postpartum care, menopause, pelvic and uterine health, sexual health, mental health and general wellness. You can read a clear historical overview in Zivian Health’s guide to the evolution of FemTech and women’s health.
Here is why the definition matters for your business. The legal team at Jones Day describes FemTech as work at the intersection of life sciences and technology that covers conditions affecting only women, conditions affecting women disproportionately, and general conditions that affect women differently from men, such as cardiovascular disease and cancer. That wider reading moves the sector far beyond period apps and into clinical medicine. For founders, a wider definition means a wider market, and also a higher bar for evidence. You can read their full commentary in the Jones Day analysis of investment in women’s health technology.
Which “FemTech” are we talking about?
Search engines and AI assistants mix these terms up all the time, so here is a quick disambiguation:
- FemTech (women’s health technology): the sector this article covers, including apps, wearables, diagnostics, devices and telehealth for women’s health.
- Femtotechnology: a theoretical physics concept about structuring matter at the femtometer scale. Wikipedia explicitly warns readers not to confuse it with FemTech.
- FemTech Azerbaijan: a Baku-based organization founded in 2020 that helps women build high-tech careers and start their own companies. Same name, different mission: career and entrepreneurship support for women.
- FemTech Analytics: a strategic analytics agency that profiles companies and publishes research across women’s health subsectors.
What are the most shocking FemTech statistics right now?
Numbers are the fastest way to understand a market, so start here. These figures come from industry reports, investor guides and academic commentary, and I recommend you copy them into your pitch deck (the slide presentation you show investors) with proper attribution.
- $41 billion to $98.8 billion: the projected FemTech market growth from 2024 to 2029, according to Freshcode. By my own calculation, that is roughly 2.4x in five years, or about 19% compound annual growth.
- More than $100 billion by 2030: the sector projection cited in a ScienceDirect viewpoint on FemTech and health equity.
- 4%: the share of healthcare R&D that addresses women’s health issues.
- 84%: the share of women who say they feel unheard in healthcare.
- 3%: FemTech’s share of total digital health spending, according to CapShift.
- $1.24 billion vs. $44 million: funding for erectile dysfunction compared with endometriosis between 2019 and 2023. That is about 28 times more money for one men’s health condition.
- $500 billion a year: estimated annual spending by women on medical expenses (PitchBook, 2023, cited by the Leeds School of Business).
- Up to £11: the estimated societal and economic return for every pound invested in reproductive health.
What do I see in this list? I see a market where buyers already spend money and suppliers have barely shown up. When women spend about $500 billion a year on healthcare and FemTech receives only 3% of digital health spending, the gap points to slow capital, and buyers keep waiting. Slow capital is a temporary condition. Founders who build credibility now will be the ones investors call when the money finally moves, and that is your FOMO moment for 2026.
For a fuller view of market forces, read the Freshcode FemTech market overview and challenges report and the CapShift investor’s guide to FemTech and health equity.
Which FemTech news stories should entrepreneurs follow this month?
Headlines come and go every week. These are the signals that I believe will still matter a year from now, each with my take on what it means for a founder.
- AI is moving into clinical-grade women’s health. In July 2025, Solence launched an AI-based digital therapeutic for PCOS (polycystic ovary syndrome), as reported by DelveInsight. A digital therapeutic is software that delivers a clinical intervention, so it sits much closer to medicine than a wellness app does. My take: the era of “track your cycle and get a cute notification” is ending. The money will follow products that change clinical outcomes.
- AI imaging is targeting underserved diagnosis. DeepLook Medical, a Connecticut-based healthtech company, builds AI imaging tools to improve breast cancer detection in patients with dense breast tissue. Its CEO, Marissa Fayer, told Jones Day: “Women react differently to everything from drug interactions, heart attack symptoms to the size of orthopedic surgical equipment. This creates barriers that have never been studied before. Without understanding the root cause, how can a doctor effectively treat their patients, which are 51% of the global population?” My take: diagnosis gaps are a goldmine for technical founders.
- Funding remains lopsided. CapShift’s numbers on endometriosis funding versus erectile dysfunction funding should shock anyone. My take: if you build for endometriosis, menopause or pelvic health, expect fewer competitors and harder fundraising at the same time. Plan for grants and impact capital from the start.
- Privacy and medical reliability are under fire. Critics cited on Wikipedia point to FemTech apps reporting false information about users’ reproductive health, questionable data-sharing practices, gender stereotyping and “epistemic injustice” (the dismissal of women as reliable sources of knowledge about their own bodies). Researchers propose ethics-by-design tools based on the capability sensitive design (CSD) framework, though it remains mostly theoretical. My take: privacy will become a purchase criterion, and founders who treat it as a feature will win trust faster.
- Low-resource settings are teaching rich markets. A ScienceDirect viewpoint argues that low-cost, locally adapted tools built for low-resource settings now influence practices in high-income countries through “bidirectional learning.” It also warns that much of FemTech’s growth remains concentrated in high-income countries and consumer apps. My take: frugal design is a competitive weapon, especially for bootstrapped founders.
- Regional FemTech hubs are forming. FemTech Analytics runs a “FemTech in Florida” project aimed at concentrating women’s health activity in one region. My take: regional programs bring local grants, pilot partners and press, and European founders should watch for similar clusters at home.
- A new generation of investors is arriving. The Leeds School of Business describes an emerging syndicate of women venture capitalists active in the space. Student Gwyneth Brass put it this way: “I think people are beginning to see the power of investing in FemTech, and it’s really exciting.” My take: build relationships with these investors before they raise their first funds.
- The name itself is being questioned. Kristin Apple, president of the strategy consultancy LINUS, takes issue with the term “FemTech” and argues that the industry is about women’s health first. My take: this debate affects how you position your brand, and I cover it below.
For a product-by-product view, the DelveInsight report on FemTech applications and companies lists product types from menstrual tracking to menopause platforms. The Leeds School of Business feature on the rise of FemTech covers investor sentiment and the naming debate.
Why is women’s health still underfunded? A founder’s take
Freshcode names three obstacles: lack of investment, because many investors still see FemTech as a niche; insufficient R&D funding; and lack of public support, rooted in historical taboos, gender bias and a venture capital industry dominated by men who often do not understand women’s health. I agree with all three. I would add a fourth that nobody likes to say out loud: many FemTech founders pitch with emotion and arrive with too little evidence.
I treat diversity as a systems problem. Women founders already have motivation and talent. What they lack is access to networks, capital, IP knowledge and safe places to practice failing. That is why I built Fe/male Switch as a game-based incubator where women rehearse pitching, negotiation and validation before they burn real money. The same logic applies to FemTech: a founder with a validated customer list, a clinical advisor and a privacy architecture beats a founder with a moving story every single time.
Here is the provocative part. Investors who skip FemTech because “it’s niche” are making a math error. Half the population is a niche only in a pitch room full of people who will never menstruate, give birth or go through menopause. Your job as a founder is to make that math error impossible to ignore, using the numbers in this article and your own customer data.
Where are the biggest FemTech opportunities for startups?
FemTech Analytics splits the sector into subsectors that make a good map for opportunity hunting. You can browse their framework on the FemTech Analytics women’s health research platform. Here is how I rate each one from a founder’s perspective:
- Reproductive health and contraception: crowded on the consumer side, open on the clinical and diagnostic side.
- Menstrual health: the birthplace of FemTech and the most saturated segment. Enter only with a sharp clinical angle.
- Pregnancy and nursing: strong demand, high liability, and real room for postpartum mental health tools.
- Menopause care: massively underserved, with buyers who have spending power and patience for good products.
- Pelvic and uterine healthcare: pelvic floor trainers and at-home diagnostics are still early, and most women have never heard of them.
- Sexual health: stigma keeps competitors away, which can work in your favor if you can handle ad platform restrictions.
- Mental health: overlaps with every other segment and offers room for hormone-aware mental health products.
- Women’s longevity: a young category with conditions like osteoporosis and cardiovascular risk that present differently in women.
- Chronic conditions: DelveInsight names endometriosis and osteoporosis as growth areas, and the funding gap in endometriosis is an open invitation.
Which business models work best in FemTech?
The Leeds School of Business notes that employers are offering more women’s health benefits. That opens a B2B (business-to-business) route where companies pay for fertility, menopause or pelvic health programs for their staff. A B2B2C model, where you sell through clinics, insurers or pharmacies to reach patients, can shorten your sales cycle once you have evidence. Pure B2C (direct-to-consumer) apps face high acquisition costs and heavy competition, so I only recommend them when you have a distribution advantage such as an existing community.
What about “picks and shovels” plays?
Every gold rush rewards people who sell tools to the miners. In FemTech, the tool gaps I see include privacy and consent infrastructure for health apps, clinical trial recruitment services focused on women, datasets that include women properly, and compliance tooling for small teams. My own work at CADChain taught me one principle that transfers directly: protection and compliance should be invisible. If a FemTech app needs users to read a 40-page privacy policy to stay safe, the product has already failed them.
How do you start a FemTech startup in 2026? A step-by-step guide
This is the playbook I would follow if I launched a FemTech company tomorrow. It reflects my bias toward cheap experiments, no-code tools and early evidence. Next steps:
A quick example of how this plays out. Picture a solo founder building a pelvic floor training product for new mothers. She interviews 30 mothers and 5 pelvic physiotherapists, finds that most women never received postpartum pelvic advice, and builds a no-code coaching flow in two weeks. She pilots it with one physiotherapy clinic, measures symptom changes over eight weeks, and then pitches employers offering parental benefits. She spends almost nothing on code, and every step produces evidence.
What mistakes kill FemTech startups?
I see the same errors in pitch competitions, accelerator cohorts and my own incubator. Avoid these and you are already ahead of most of the field.
- Building another period tracker. The menstrual tracking segment is crowded. Without a clinical angle, you compete on marketing budget alone.
- Treating privacy as a legal afterthought. The criticism of FemTech data-sharing is public and growing. One data scandal can end a young company.
- Making medical claims without evidence. Critics have already documented apps giving false reproductive health information. Regulators and journalists read those reports too.
- Using pink, shrink-it design and stereotypes. Researchers flag gender stereotyping as a recurring FemTech failure. Women are adults with complex lives, so design for that.
- Selling fear. Feminist researchers argue that some FemTech exploits women’s health anxieties. Products built on anxiety create churn and distrust.
- Ignoring women outside rich countries. The ScienceDirect viewpoint shows growth concentrated in high-income markets. Global designs and frugal pricing open far bigger audiences.
- Adding badges instead of outcomes. My principle: gamification without skin in the game is useless. Streaks and points mean nothing unless they change a health behavior you can measure.
- Pitching only to generalist investors. If an investor needs a biology lesson on menopause during your pitch, move on and find investors who already understand the problem.
Is the word “FemTech” helping or hurting the sector?
My first degrees are in linguistics, so I care about this debate more than most founders do. Language works as an interface between people and systems. A label decides which shelf a product lands on, which investor reads the deck, and which journalist covers the launch. The term “FemTech” gave Ida Tin and her peers a shared banner in 2016, and that banner pulled scattered products into one recognizable category.
Kristin Apple’s critique has merit, though. When cardiovascular devices and cancer imaging sit under a word that sounds like a consumer gadget category, serious clinical companies get underestimated. My practical advice: use “FemTech” for discovery and community, because that is what people search for. Use clinical language, such as “women’s health diagnostics” or “menopause digital therapeutic,” on your website, in your deck and in grant applications. Two labels, two audiences, one company.
What do I expect from FemTech in 2027?
These are opinions, clearly labeled as mine, based on the data above and on what I see as a European founder and incubator operator.
- Clinical proof will separate winners from apps. Products like digital therapeutics for PCOS show where funding will concentrate.
- Privacy will become a marketing message. Companies will advertise what they do NOT collect.
- AI will find gaps in women’s data. Imaging and symptom models trained mostly on men will face public scrutiny, and companies that fix those datasets will gain leverage with hospitals.
- Menopause and longevity will attract the next funding wave. The buyers have money, and the products are still primitive.
- Solo founders will compete with funded teams. AI agents and no-code tools now handle research, content and prototyping, so a small team can test ideas at a fraction of past costs.
FemTech FAQ: quick answers for founders
Who coined the term FemTech?
Ida Tin, the Danish founder of the period tracking app Clue, coined the term in 2016 to group technology products for women’s health under one name.
How big is the FemTech market?
Freshcode projects growth from $41 billion in 2024 to $98.8 billion by 2029. A ScienceDirect viewpoint cites projections above $100 billion by 2030.
Why do FemTech startups struggle to raise money?
Investors often see the sector as niche, R&D funding for women’s health is low (about 4% of the total), and historical taboos plus a venture capital industry dominated by men slow decisions. FemTech receives only about 3% of digital health spending.
Is a FemTech app a medical device?
It depends on your claims. Apps that diagnose, treat or prevent conditions may fall under medical device rules, while general wellness apps usually do not. Check with a regulatory advisor before you write your marketing copy.
Which FemTech segments are least crowded?
Menopause care, pelvic health, women’s longevity and chronic conditions such as endometriosis and osteoporosis show high need and comparatively few well-funded competitors.
What should you do next?
The FemTech news for November 2026 boils down to one tension: demand is massive, and capital is still catching up. Women spend hundreds of billions on healthcare each year, while conditions like endometriosis receive a sliver of the funding that men’s health products get. That gap is painful for patients and a real opening for founders willing to do the slow work of evidence, privacy and clinical partnerships. My belief has stayed the same through every venture I have built: women need infrastructure, meaning tools, playbooks and proof, far more than they need another motivational panel.
Here is your short action list for this month:
- Choose one underserved condition from the opportunity list above.
- Book 10 customer interviews this week and 2 clinician calls next week.
- Write a one-page privacy promise before you write a single line of code.
- Build a no-code prototype within 14 days and put it in front of real users.
- List five grants or impact funds that support women’s health or health equity.
- Add the funding-gap statistics from this article to your pitch deck, with sources.
Startups are a strategic game, and the winners collect information, assets and relationships faster than everyone else. FemTech rewards founders who start collecting now, before the investor crowd arrives. If you want to rehearse that game in a low-risk setting first, that is exactly why I built Fe/male Switch. Either way, start this month, because the founders who show up early in an underfunded market are the ones who set its rules.
Violetta Bonenkamp (Mean CEO) is a parallel entrepreneur, co-founder and CEO of CADChain, founder of the women-first startup game Fe/male Switch, and was named one of the Top 100 most influential women in European startups and VC by EU-Startups.
People Also Ask:
What is the meaning of FemTech?
FemTech, short for "female technology," refers to software, apps, diagnostics, medical devices, and services that use technology to improve women's health. It covers conditions unique to women and conditions that affect women differently or more often than men. The term applies to both consumer products and clinical tools.
What is the FemTech industry?
The FemTech industry is the business sector of companies building technology for women's health and wellness. Early companies focused mostly on period tracking and fertility. The industry now also covers pregnancy, maternal care, menopause, pelvic and sexual health, and chronic conditions such as heart disease, osteoporosis, and autoimmune disorders. It includes startups, healthcare providers, researchers, and investors.
What are examples of FemTech?
Common examples of FemTech include:
- Period and fertility tracking apps like Clue and Flo
- Ovulation kits and smart tampons for reproductive health monitoring
- Fetal heart monitors and virtual prenatal visits for pregnancy care
- Wearables and telehealth services for menopause symptoms such as hot flashes
- App-guided pelvic floor trainers and sexual wellness devices
- Diagnostics for breast cancer, heart disease, and bone health
What are the risks associated with FemTech?
The biggest concern is data privacy. Many apps collect sensitive information about periods, sexual activity, and pregnancy, and that data can be shared with third parties. In the U.S., since Roe v. Wade was overturned, it could also be used in legal cases. Other risks include:
- Products that lack clinical testing
- Apps that are not regulated as medical devices
- Inaccurate cycle or fertility predictions
- Tools that may reinforce narrow gender norms around fertility and pregnancy
Who coined the term FemTech?
Ida Tin, a Danish entrepreneur and founder of the period-tracking app Clue, coined the term in 2016. She wanted a clear name for the category that would draw investor attention to a long-overlooked area of healthcare.
What are some well-known FemTech companies?
Well-known FemTech companies include:
- Clue and Flo: period and cycle tracking
- Natural Cycles: an FDA-cleared birth control app
- Elvie: wearable breast pumps and pelvic floor trainers
- Maven Clinic: virtual care for fertility, pregnancy, and parenting
- Kindbody and Carrot Fertility: fertility care and benefits
- Midi Health: menopause care
Many smaller startups focus on specific conditions like endometriosis, PCOS, and postpartum recovery.
What kinds of FemTech products are available?
FemTech products range from mobile apps to medical devices. Consumer products include:
- Cycle trackers
- Ovulation and pregnancy tests that sync with phones
- At-home hormone and fertility tests
- Smart breast pumps and pelvic floor trainers
- Menopause symptom trackers
- Telehealth subscriptions
On the clinical side, doctors use FemTech diagnostic tests and devices to detect conditions that affect women.
How big is the FemTech market?
The global FemTech market has grown into a multi-billion-dollar industry. Its growth comes from wider use of digital health tools and mobile apps, rising investor interest, and more employers offering women's health benefits such as fertility and menopause support. Estimates of its exact size vary by research firm, but most forecasts expect steady growth over the next decade.
Why does FemTech matter for women's health?
For decades, medical research and clinical trials treated the male body as the default. This left gaps in how women's conditions are studied, diagnosed, and treated. Heart disease in women is more likely to be missed or diagnosed late, and endometriosis often takes years to diagnose. FemTech aims to close these gaps with tools, information, and care designed around women's bodies.
What jobs are available in FemTech?
FemTech companies hire for many of the same roles as other health tech firms, including:
- Software engineers
- Product managers
- Data scientists
- Clinicians and medical researchers
- Regulatory specialists
- Marketers and customer support staff
Many FemTech companies are digital-first startups, so many of these jobs are remote. Health tech job boards, women's health job boards, and LinkedIn are good places to start a search.
FAQ on FemTech Funding, Growth and Startup Strategy in 2026
Which investors fund FemTech startups besides traditional VCs?
Corporate healthcare and pharma venture arms, impact investors, angel investors and female-led funds all back women's health ventures. Match each investor type to your stage. Approach angels and female-led funds at pre-seed, impact capital for equity-focused products, and corporate arms for clinical partnerships. Explore the FemTech investor landscape in April 2026
Why do FemTech market size forecasts vary so widely?
Estimates range from $75 billion by 2030 to $206.84 billion by 2033, largely because analysts define the category differently. Some count only apps and devices, while others include pharmaceuticals and clinical care. In your pitch deck, state which definition you use and size your specific segment. See the latest FemTech market growth forecasts
How can FemTech startups avoid sex bias in AI and device data?
Build sex-specific biology into your data models from day one, train algorithms on diverse datasets across ages and ethnicities, and test early with real users. Document data provenance so hospitals and regulators can audit results. The guiding rule is to build with women, not just for women. Read how to build better FemTech products with diverse data
How can a FemTech startup win employer contracts and reimbursement?
Think like a systems founder and integrate into full-stack care pathways instead of launching a single-purpose app. Employers and payers buy clinical trust, measurable outcomes and a clear reimbursement path. Prepare cost-savings data, care-workflow integration plans and AI governance documentation before approaching benefits managers. Learn why FemTech is shifting to full-stack care models
What does Midi Health's $100 million round signal for early-stage founders?
The round shows that institutional investors now back clinical midlife and hormonal care at scale. Early-stage founders should prioritize early revenue, transparent data practices and ethical AI use. Large rounds raise investor expectations for traction, so a strong mission alone will not close a deal. Discover what Midi Health's funding means for FemTech startups
Does FemTech include autoimmune diseases, migraines and other chronic conditions?
Yes. Conditions that disproportionately affect women, including autoimmune diseases, migraines and other chronic illnesses, fall within FemTech's scope. These areas remain underexplored compared with fertility apps. Founders with clinical partners can build differentiated symptom-tracking, diagnostic or care-coordination tools and face fewer direct competitors. Read about FemTech's role in chronic disease management
Where can FemTech founders find industry research and peer communities?
FemTech Analytics publishes subsector research and company profiles, and it runs a Women's Health Club. Use these resources to benchmark competitors, identify partners and spot regional hubs. Pair them with local accelerators and clinician networks to validate ideas and find pilot sites faster. Join the FemTech Analytics Women's Health Club
Should FemTech products serve users who don't identify as women?
Yes. CapShift's investor guide frames FemTech as serving women and anyone with female organs, which includes trans men and non-binary people. Use inclusive, anatomy-based language in onboarding and avoid gendered assumptions in symptom logic. Test your copy with diverse users to expand reach and build trust. Read CapShift's investor guide to FemTech and health equity
How can co-design with lived experience improve FemTech products?
Involving patients, midwives and community health workers in design surfaces real barriers that desk research misses. A ScienceDirect viewpoint argues that FemTech's path forward centers on lived experience and co-design. Run paid co-creation sessions, publish what you changed based on feedback, and test frugal versions for low-resource markets. Explore research on FemTech innovation and health equity
Where can women founders get structured support to launch a FemTech venture?
Women-led startups face a funding gap similar to FemTech's own, so structured playbooks matter. Use frameworks that cover validation, grant applications, investor outreach and negotiation. Practice in low-risk settings before spending real money, and find mentors who understand both clinical and commercial realities. Get the Female Entrepreneur Playbook for 2026
